Wall Street Zen Downgrades Fulcrum Therapeutics (NASDAQ:FULC) to Sell

Fulcrum Therapeutics (NASDAQ:FULC) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

A number of other research firms have also issued reports on FULC. Piper Sandler reaffirmed an “overweight” rating and set a $23.00 target price (up previously from $16.00) on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Stifel Nicolaus set a $25.00 price target on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. Truist Financial upped their price objective on shares of Fulcrum Therapeutics from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Wednesday, October 8th. Finally, Bank of America raised their target price on shares of Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a research note on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, Fulcrum Therapeutics has an average rating of “Moderate Buy” and an average target price of $19.11.

Fulcrum Therapeutics Price Performance

Shares of Fulcrum Therapeutics stock opened at $10.14 on Friday. The stock has a market capitalization of $548.78 million, a P/E ratio of -8.59 and a beta of 3.20. The business has a 50 day simple moving average of $10.89 and a two-hundred day simple moving average of $8.88. Fulcrum Therapeutics has a 12 month low of $2.32 and a 12 month high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). As a group, research analysts anticipate that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Insider Transactions at Fulcrum Therapeutics

In other Fulcrum Therapeutics news, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $11.87, for a total value of $178,050.00. Following the transaction, the director directly owned 469,864 shares in the company, valued at $5,577,285.68. The trade was a 3.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the completion of the sale, the insider directly owned 6,053,960 shares of the company’s stock, valued at approximately $84,634,360.80. This trade represents a 40.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 4,205,139 shares of company stock worth $58,711,943 over the last ninety days. 7.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Fulcrum Therapeutics

Large investors have recently modified their holdings of the business. Quarry LP acquired a new stake in shares of Fulcrum Therapeutics during the 3rd quarter worth about $35,000. Russell Investments Group Ltd. boosted its stake in Fulcrum Therapeutics by 4,209.3% during the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after buying an additional 9,092 shares during the period. Farther Finance Advisors LLC increased its position in shares of Fulcrum Therapeutics by 108.3% during the third quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after acquiring an additional 3,697 shares during the last quarter. Assetmark Inc. acquired a new stake in shares of Fulcrum Therapeutics during the third quarter valued at about $88,000. Finally, Vanguard Personalized Indexing Management LLC raised its stake in shares of Fulcrum Therapeutics by 26.1% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company’s stock valued at $89,000 after acquiring an additional 2,677 shares during the period. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.